• ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 LIVE!™
Insights
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Client Handouts
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Coverage
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Largest-ever canine genomics research reveals human-canine oncology connection

January 28, 2022
dvm360 Staff

The study analyzed canine cancer in over 700 dogs across 23 tumor types and can help progress precision cancer therapeutics.

One Health Company has unveiled newly published research from the largest ever clinico-genomics study in dogs with findings that can potentially help advance precision oncology drug development for both dogs and humans.1

"There is a remarkable similarity between human and canine tumor biology, specifically, genomics. And because tumors progress more quickly in dogs, this creates a paradigm for preclinical research that can accelerate the development of precision cancer therapeutics for both canines and humans, without compromising safety," Christina Lopes, PhD, MS, co-founder and CEO of the One Health Company, explained in a company release.2

"This much-needed research can ultimately improve clinical trial success, closing the vast oncology unmet needs—on both sides of the leash," she added.

Conducted in partnership with Shaying Zhao, PhD, professor of biochemistry and molecular biology at the University of Georgia, the study analyzed canine cancer in over 700 dogs from 96 breeds compared to over 24,000 human cancer samples.1

Current drug development is reliant on mouse models for preclinical efficacy, which yields an 89% failure rate for novel cancer therapeutics in human clinical trial studies.3 Furthermore, only 3 to 6% of human cancer patients participate in clinical trials, thus increasing drug discovery and research costs for new therapeutics already costing $2.6 billion to get FDA-approved and taking approximately 10 years to be available on the market.

According to the release, using the One Health Company's FidoCureNext Generation Sequencing Genomic Panel, the study compared regions of the DNA that are more susceptible to cancer-causing mutations.2 Twenty mutational hotspots were detected in the canine genome, and 13 of these orthologous hotspot mutations found are also often displayed in human cancers.

"This study validates findings from prior smaller sample canine genomics research and emphasizes important parallels between the human and canine tumor genomes to identify clinically actionable mutations, which in turn provides a powerful platform informing and advancing precision oncology drug development across the board," commented Zhao.2

References

  1. Rodrigues L, Watson J, Feng Y, et al. Shared hotspot mutations in spontaneously arising cancers position dog as an unparalleled comparative model for precision therapeutics. Annu Rev Cancer Biol. 2021. doi: 10.1101/2021.10.22.465469
  2. Largest-ever canine genomics study establishes link between human and canine oncology. News release. One Health Company. January 26, 2022. Accessed January 27, 2022. https://www.prnewswire.com/news-releases/largest-ever-canine-genomics-study-establishes-link-between-human-and-canine-oncology-301468587.html
  3. Rybinski B, Hosgood DH, Wiener S L, Weiser DA. Preclinical metrics correlate with drug activity in phase II trials of targeted therapies for non-small cell lung cancer. Front Oncol. 2020;(5)10. doi: 10.3389/fonc.2020.587377

Related Content:

OncologyClinicalMedicalOne Health
Completing a neurological exam is like following a cooking recipe
Completing a neurological exam is like following a cooking recipe
Trends in canine oncology
Trends in canine oncology
Veterinary medicine in the military with Zachary Tooley
Veterinary medicine in the military with Zachary Tooley

Latest News

Pet Acoustics opens contest submissions for singing canines

Dr. Marty Pets announces new designs for its products

Brookfield Zoo welcomes South American tapir calf

Veterinary medicine in the military with Zachary Tooley

View More Latest News